Cilostazol prevents amyloid β peptide 25-35-induced memory impairment and oxidative stress in mice

British Journal of Pharmacology

Volumn 161, Issue 8, 2010, Pages 1899-1912

  Hiramatsu, Masayuki ^a   Takiguchi, Osanao ^a   Nishiyama, Aki ^a   Mori, Hiromasa ^a,b  

^a MEIJO UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Amyloid peptide 25 35; Cilostazol; Lipid peroxidation; Malondialdehyde; Memory; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[25-35]; CILOSTAZOL; INTERLEUKIN 1BETA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FRONTAL CORTEX; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASPIRIN; AVOIDANCE LEARNING; CYTOKINES; DISEASE MODELS, ANIMAL; FRONTAL LOBE; HIPPOCAMPUS; MALE; MALONDIALDEHYDE; MAZE LEARNING; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; TETRAZOLES;

EID: 78649406219     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01014.x     Document Type: Article

References (47)

1. Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T (2007). A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav Brain Res 180: 139-145.
2. Alkam T, Nitta A, Mizoguchi H, Itoh A, Murai R, Nagai T et al. (2008). The extensive nitration of neurofilament light chain in the hippocampus is associated with the cognitive impairment induced by amyloid beta in mice. J Pharmacol Exp Ther 327: 137-147.
3. Arai H, Takahashi T (2009). A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am J Geriatr Psychiatry 17: 353-354.
4. Chen L, Na R, Gu M, Richardson A, Ran Q (2008). Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. J Neurochem 107: 197-207.
5. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW (2002). Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300: 787-793.
6. Fang F, Liu GT (2006). Protective effects of compound FLZ on beta-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment. Acta Pharmacol Sin 27: 651-658.
7. Greilberger J, Koidl C, Greilberger M, Lamprecht M, Schroecksnadel K, Leblhuber F et al. (2008). Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res 42: 633-638.
8. Haley TJ, McCormick WG (1957). Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12: 12-15.
9. Hiramatsu M, Inoue K (1999). Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. Br J Pharmacol 127: 655-660.
10. Hiramatsu M, Inoue K (2000a). Des-tyrosine(1) dynorphin A-(2-13) improves carbon monoxide-induced impairment of learning and memory in mice. Brain Res 859: 303-310.
11. Hiramatsu M, Inoue K (2000b). Improvement by low doses of nociceptin on scopolamine-induced impairment of learning and/or memory. Eur J Pharmacol 395: 149-156.
12. Hiramatsu M, Inoue K, Kameyama T (2000). Dynorphin A-(1-13) and (2-13) improve beta-amyloid peptide-induced amnesia in mice. Neuroreport 11: 431-435.
13. Itoh J, Ukai M, Kameyama T (1993). Dynorphin A-(1-13) markedly improves scopolamine-induced impairment of spontaneous alternation performance in mice. Eur J Pharmacol 236: 341-345.
14. Kamat PK, Tota S, Saxena G, Shukla R, Nath C (2010). Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. Brain Res 1309: 66-74.
15. Kim KY, Shin HK, Choi JM, Hong KW (2002). Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300: 709-715.
16. Kim MJ, Lee JH, Park SY, Hong KW, Kim CD, Kim KY et al. (2006). Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation. Pharmacol Res 54: 261-267.
17. Kimura Y, Tani T, Kanbe T, Watanabe K (1985). Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35: 1144-1149.
18. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS et al. (2005). Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36: 782-786.
19. Lee JH, Kim KY, Lee YK, Park SY, Kim CD, Lee WS et al. (2004). Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther 308: 896-903.
20. Lee JH, Park SY, Lee WS, Hong KW (2005). Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. Neurol Res 27: 483-492.
21. Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM et al. (2006). Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res 1082: 182-191.
22. Lee JH, Park SY, Shin YW, Kim CD, Lee WS, Hong KW (2007). Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats. Brain Res 1185: 246-255.
23. Lin HB, Yang XM, Li TJ, Cheng YF, Zhang HT, Xu JP (2009). Memory deficits and neurochemical changes induced by C-reactive protein in rats: implication in Alzheimer's disease. Psychopharmacology (Berl) 204: 705-714.
24. Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T et al. (2009). Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 157: 1270-1277.
25. Markesbery WR (1997). Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23: 134-147.
26. Markesbery WR, Lovell MA (1998). Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-36.
27. Maurice T, Lockhart BP, Privat A (1996). Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181-193.
28. Mecocci P (2004). Oxidative stress in mild cognitive impairment and Alzheimer disease: a continuum. J Alzheimers Dis 6: 159-163.
29. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL et al. (2007). Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 27: 5394-5404.
30. Meunier J, Ieni J, Maurice T (2006). The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 149: 998-1012.
31. Miyamoto N, Tanaka R, Zhang N, Shimura H, Onodera M, Mochizuki H et al. (2009). Crucial role for Ser133-phosphorylated form of cyclic AMP-responsive element binding protein signaling in the differentiation and survival of neural progenitors under chronic cerebral hypoperfusion. Neuroscience 162: 525-536.
32. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ 2nd, Morrow JD (1999). The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am J Pathol 155: 863-868.
33. Muir K, Lees KR (1997). Thrombolytic therapy for acute ischaemic stroke. Lancet 350: 1476-1477.
34. Narimatsu N, Harada N, Kurihara H, Nakagata N, Sobue K, Okajima K (2009). Donepezil improves cognitive function in mice by increasing the production of insulin-like growth factor I in the hippocampus. J Pharmacol Exp Ther 330: 2-12.
35. Palmer AM (2002). Pharmacotherapy for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 23: 426-433.
36. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA et al. (1998). Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152: 871-877.
37. Praticò D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001). Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21: 4183-4187.
38. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R (2007). Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans 35 (Pt 5): 1219-1223.
39. Sarter M, Bodewitz G, Stephens DN (1988). Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl) 94: 491-495.
40. Slater TF (1984). Free-radical mechanisms in tissue injury. Biochem J 222: 1-15.
41. Sugaya K, Uz T, Kumar V, Manev H (2000). New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol 82: 85-94.
42. Szekely CA, Green RC, Breitner JC, Østbye T, Beiser AS, Corrada MM et al. (2008). No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70: 2291-2298.
43. Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A (2001). Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand 103: 166-174.
44. Tran MH, Yamada K, Olariu A, Mizuno M, Ren XH, Nabeshima T (2001). Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 15: 1407-1409.
45. Trubetskaya VV, Stepanichev MY, Onufriev MV, Lazareva NA, Markevich VA, Gulyaeva NV (2003). Administration of aggregated beta-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo. Neurosci Behav Physiol 33: 95-98.
46. Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T (2006). Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 37: 1539-1545.
47. Zhao J, Harada N, Kurihara H, Nakagata N, Okajima K (2010). Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor I in the hippocampus. Neuropharmacology 58: 774-783.